Advertisements


Acasti Pharma reports Q3 EPS (18c), one est. (16c)

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 14th, 2020

Acasti Pharma reports last patient visit in TRILOGY 1 Phase 3 trial of CaPre

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallNov 26th, 2019

Acasti Pharma reports Q2 EPS (34c), one est. (16c)

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallNov 13th, 2019

Acasti Pharma reports Q1 EPS (15c), one est. (16c)

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 14th, 2019

Acasti Pharma reports on positive feedback at Atherosclerosis symposium

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 11th, 2018

Acasti Pharma price target lowered to $3 from $6 at H.C. Wainwright

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 18th, 2020

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2020

LAVAL, Québec, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ:ACST, TSXV:ACST), a biopharmaceutical innovator focused on the research, development and commer.....»»

Category: earningsSource: benzingaFeb 14th, 2020

Acasti Pharma to seek FDA guidance prior to unblinding TRILOGY 2 data

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 14th, 2020

Acasti Pharma sees cash sufficient through at least December 2020

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 14th, 2020

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2019

VA.....»»

Category: earningsSource: benzingaFeb 14th, 2020

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2019

VANCOUVER and HOUSTON, TX, F.....»»

Category: earningsSource: benzingaFeb 14th, 2020

GC Pharma Reports Full Year 2019 Results

All consolidated entities revenues grew plus compared to prior year YONGIN, South Korea, Feb. 12, 2020 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 00628.....»»

Category: earningsSource: benzingaFeb 12th, 2020

Acasti Pharma announces investigation into Phase 3 TRILOGY 1 results

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 10th, 2020

MEI Pharma reports Q2 EPS (26c), consensus (17c)

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 6th, 2020

Mid-Afternoon Market Update: Acasti Pharma Falls On Failed Late-Stage Trial; Verona Pharma Shares Gain

Toward the end of trading Monday, the Dow traded up 0.17% to 28872.00 while the NASDAQ rose 0.88% to 9,259.66. The S&P also rose, gaining 0.56% to 3,283.62. 0 read more.....»»

Category: blogSource: benzingaJan 13th, 2020

GW Pharma Reports Preliminary Q4 Revenue Of $108M, "Exceptional" Launch Year For Epidiolex

GW Pharmaceuticals plc (NASDAQ: GWPH) issued preliminary unaudited fourth-quarter financial results Sunday that show .....»»

Category: earningsSource: benzingaJan 13th, 2020

Acasti Pharma announces results from TRILOGY 1 Phase 3 trial of CaPre

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 13th, 2020

Acasti Pharma News: Why ACST Stock Is Plummeting 24% Today

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acast.....»»

Category: topSource: investorplaceDec 24th, 2019

B. Riley FBR continues to like Acasti Pharma risk-reward going into 2020

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 24th, 2019

Acasti Pharma to resume trading at 9:15 am ET

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 24th, 2019

Acasti Pharma to report CaPre phase 3 trial results in January

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 23rd, 2019